Plain-English translation of NCT07660614 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is one of the first times this treatment has been tested in people.
This is an early-stage trial testing a new medication called , which is injected directly into the fluid surrounding your spinal cord. The medication is designed to target a specific genetic pathway involved in ALS. Researchers want to understand whether this treatment is safe and whether it might help slow down the disease's progression.
ALS is a serious condition that gradually weakens muscles over time, and current treatment options are limited. This medication represents a new approach based on genetic research, and this trial will see whether the treatment can be safely given to patients and whether it shows promise in slowing ALS symptoms.
You likely qualify if…
You likely don't qualify if…
You would visit the study site about 9 times over several months, with one overnight stay. At each visit, you'll have physical exams, nerve and muscle strength tests, heart monitoring, and blood or urine samples collected. You'll also receive spinal injections of either the new medication or a placebo (a non-active solution), and researchers will regularly check your lung function, speech, and overall ALS symptoms. Between visits, you'll have phone or video check-ins with the study team.
AI-generated summary from trial data · Aug 21, 2026 · Not medical advice
Germany
Italy
Netherlands
Sweden